LJPC stock is moving higher into the close of trading on January 9, 2020, after the company reported awesome revenue growth.

La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced preliminary GIAPREZA™ (angiotensin II) net sales for the three and twelve months ended December 31, 2019. For the three months ended December 31, 2019, preliminary GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018 and up 26% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.

As of December 31, 2019, La Jolla had approximately $87.8 million in cash and cash equivalents, compared to $104.8 million as of September 30, 2019. Net cash used in operating activities for the three months ended December 31, 2019 was approximately $17.0 million. La Jolla has no debt.

H.C. Wainwright analyst Edward White maintained a Neutral rating on La Jolla following the company’s preannouncement of Q4 and FY19 Giapreza sales, which were $7.2M and $23.1M, respectively. While the sales were higher than the analyst had forecast, he continues to believe they will be immaterial in 2020, and maintained a Neutral rating due to the company’s discontinuation of its pipeline product LJPC-401 and sudden departure of its CEO.

finviz dynamic chart for  ljpc
La Jolla Pharmaceutical News From Google